Publications (original articles or review articles) published in 2023 from OUS - Section for head and neck oncology
11 publications found
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
PLoS One, 18 (2), e0281166
DOI 10.1371/journal.pone.0281166, PubMed 36730349
An HPV-Vaccinated Patient With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
JAMA Otolaryngol Head Neck Surg, 149 (1), 92-94
DOI 10.1001/jamaoto.2022.3762, PubMed 36416857
Automatic gross tumor segmentation of canine head and neck cancer using deep learning and cross-species transfer learning
Front Vet Sci, 10, 1143986
DOI 10.3389/fvets.2023.1143986, PubMed 37026102
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
JAMA Oncol (in press)
DOI 10.1001/jamaoncol.2023.0147, PubMed 37022706
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
BMJ Open, 13 (3), e070071
DOI 10.1136/bmjopen-2022-070071, PubMed 36940951
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice
Lancet Oncol, 24 (5), e197-e206
DOI 10.1016/S1470-2045(23)00110-9, PubMed 37142381
2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data
Front Neuroinform, 16, 1056068
DOI 10.3389/fninf.2022.1056068, PubMed 36743439
[Not Available]
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0314, PubMed 36718891
Serious Long-Term Effects of Head and Neck Cancer from the Survivors' Point of View
Healthcare (Basel), 11 (6)
DOI 10.3390/healthcare11060906, PubMed 36981562
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Crit Care, 27 (1), 9
DOI 10.1186/s13054-022-04205-8, PubMed 36627655
Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway
Future Oncol, 19 (3), 205-215
DOI 10.2217/fon-2022-0969, PubMed 36974621